Cardiff Oncology, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Cardiff Oncology, Inc. entered into employment agreements effective August 10, 2026 with three executives: Mani Mohindru, Ph.D. as President & CEO ($655,000 base + 55% bonus + 800,000 ISOs); Joshua Muntner as CFO ($475,000 base + 40% bonus + 486,650 ISOs); and Ajay Aggarwal, M.D. as COO ($490,000 base + 40% bonus + 400,000 ISOs). All agreements run through August 10, 2029 with auto-renewal, 12-month severance for CEO and 9-month for CFO/COO upon termination without cause, and full equity acceleration upon change of control within 12 months (CEO) or 9 months (CFO/COO) of termination.
Why this rating
Executive employment agreements are routine disclosure for a public company. Combined ~$1.62M annual base salary (~0.8% of $205M market cap) plus equity grants are standard, not transformational. No change of control or material business impact.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.